Literature DB >> 10747879

Evolution of human and non-human primate CC chemokine receptor 5 gene and mRNA. Potential roles for haplotype and mRNA diversity, differential haplotype-specific transcriptional activity, and altered transcription factor binding to polymorphic nucleotides in the pathogenesis of HIV-1 and simian immunodeficiency virus.

S Mummidi1, M Bamshad, S S Ahuja, E Gonzalez, P M Feuillet, K Begum, M C Galvis, V Kostecki, A J Valente, K K Murthy, L Haro, M J Dolan, J S Allan, S K Ahuja.   

Abstract

Polymorphisms in CC chemokine receptor 5 (CCR5), the major coreceptor of human immunodeficiency virus 1 (HIV-1) and simian immunodeficiency virus (SIV), have a major influence on HIV-1 transmission and disease progression. The effects of these polymorphisms may, in part, account for the differential pathogenesis of HIV-1 (immunosuppression) and SIV (natural resistance) in humans and non-human primates, respectively. Thus, understanding the genetic basis underlying species-specific responses to HIV-1 and SIV could reveal new anti-HIV-1 therapeutic strategies for humans. To this end, we compared CCR5 structure/evolution and regulation among humans, apes, Old World Monkeys, and New World Monkeys. The evolution of the CCR5 cis-regulatory region versus the open reading frame as well as among different domains of the open reading frame differed from one another. CCR5 cis-regulatory region sequence variation in humans was substantially higher than anticipated. Based on this variation, CCR5 haplotypes could be organized into seven evolutionarily distinct human haplogroups (HH) that we designated HHA, -B, -C, -D, -E, -F, and -G. HHA haplotypes were defined as ancestral to all other haplotypes by comparison to the CCR5 haplotypes of non-human primates. Different human and non-human primate CCR5 haplotypes were associated with differential transcriptional regulation, and various polymorphisms resulted in modified DNA-nuclear protein interactions, including altered binding of members of the NF-kappaB family of transcription factors. We identified novel CCR5 untranslated mRNA sequences that were conserved in human and non-human primates. In some primates, mutations at exon-intron boundaries caused loss of expression of selected CCR5 mRNA isoforms or production of novel mRNA isoforms. Collectively, these findings suggest that the response to HIV-1 and SIV infection in primates may have been driven, in part, by evolution of the elements controlling CCR5 transcription and translation.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10747879     DOI: 10.1074/jbc.M000169200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  76 in total

1.  Global survey of genetic variation in CCR5, RANTES, and MIP-1alpha: impact on the epidemiology of the HIV-1 pandemic.

Authors:  E Gonzalez; R Dhanda; M Bamshad; S Mummidi; R Geevarghese; G Catano; S A Anderson; E A Walter; K T Stephan; M F Hammer; A Mangano; L Sen; R A Clark; S S Ahuja; M J Dolan; S K Ahuja
Journal:  Proc Natl Acad Sci U S A       Date:  2001-04-24       Impact factor: 11.205

2.  Complex signatures of natural selection at the Duffy blood group locus.

Authors:  Martha T Hamblin; Emma E Thompson; Anna Di Rienzo
Journal:  Am J Hum Genet       Date:  2001-12-20       Impact factor: 11.025

3.  A strong signature of balancing selection in the 5' cis-regulatory region of CCR5.

Authors:  Michael J Bamshad; Srinivas Mummidi; Enrique Gonzalez; Seema S Ahuja; Diane M Dunn; W Scott Watkins; Stephen Wooding; Anne C Stone; Lynn B Jorde; Robert B Weiss; Sunil K Ahuja
Journal:  Proc Natl Acad Sci U S A       Date:  2002-07-29       Impact factor: 11.205

4.  Association test algorithm between a qualitative phenotype and a haplotype or haplotype set using simultaneous estimation of haplotype frequencies, diplotype configurations and diplotype-based penetrances.

Authors:  Toshikazu Ito; Eisuke Inoue; Naoyuki Kamatani
Journal:  Genetics       Date:  2004-12       Impact factor: 4.562

5.  Concordance of CCR5 genotypes that influence cell-mediated immunity and HIV-1 disease progression rates.

Authors:  Gabriel Catano; Zoya A Chykarenko; Andrea Mangano; J-M Anaya; Weijing He; Alison Smith; Rosa Bologna; Luisa Sen; Robert A Clark; Andrew Lloyd; Ludmila Shostakovich-Koretskaya; Sunil K Ahuja
Journal:  J Infect Dis       Date:  2011-01-15       Impact factor: 5.226

6.  Genetic variations in the receptor-ligand pair CCR5 and CCL3L1 are important determinants of susceptibility to Kawasaki disease.

Authors:  Jane C Burns; Chisato Shimizu; Enrique Gonzalez; Hemant Kulkarni; Sukeshi Patel; Hiroko Shike; Robert S Sundel; Jane W Newburger; Sunil K Ahuja
Journal:  J Infect Dis       Date:  2005-06-08       Impact factor: 5.226

Review 7.  Mendelian randomization: potential use of genetics to enable causal inferences regarding HIV-associated biomarkers and outcomes.

Authors:  Weijing He; John Castiblanco; Elizabeth A Walter; Jason F Okulicz; Sunil K Ahuja
Journal:  Curr Opin HIV AIDS       Date:  2010-11       Impact factor: 4.283

Review 8.  Human Genetic Variation and HIV/AIDS in Papua New Guinea: Time to Connect the Dots.

Authors:  Rajeev K Mehlotra
Journal:  Curr HIV/AIDS Rep       Date:  2018-12       Impact factor: 5.071

9.  Distribution of chemokine receptor CCR2 and CCR5 genotypes and their relative contribution to human immunodeficiency virus type 1 (HIV-1) seroconversion, early HIV-1 RNA concentration in plasma, and later disease progression.

Authors:  Jianming Tang; Brent Shelton; Nina J Makhatadze; Yuting Zhang; Margaret Schaen; Leslie G Louie; James J Goedert; Eric C Seaberg; Joseph B Margolick; John Mellors; Richard A Kaslow
Journal:  J Virol       Date:  2002-01       Impact factor: 5.103

10.  Influence of CCR5 and CCR2 genetic variants in the resistance/susceptibility to HIV in serodiscordant couples from Colombia.

Authors:  Wildeman Zapata; Wbeimar Aguilar-Jiménez; Nicolás Pineda-Trujillo; Winston Rojas; Hernando Estrada; María T Rugeles
Journal:  AIDS Res Hum Retroviruses       Date:  2013-11-09       Impact factor: 2.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.